Dr.ย Jae-Lyunย Lee
MD, PhD
Professor, Medical Oncology โ Genitourinary Oncology
corporate_fareAsan Medical Center, Seoul, South Korea
Jae-Lyun Lee
MD, PhD
Prof. Jae-Lyun Lee is a medical oncologist at Asan Medical Center in Seoul, South Korea, with a focused clinical and research expertise in genitourinary oncology. He holds the position of Professor in the Department of Oncology at the University of Ulsan College of Medicine and serves as Director of the Genitourinary Cancer Center at Asan Cancer Hospital.
Prof. Lee's clinical practice centres on advanced urological malignancies โ including urothelial carcinoma, bladder cancer, upper tract urothelial carcinoma, renal cell carcinoma, and rare genitourinary cancers such as urachal cancer. He is affiliated with multiple specialist units at Asan Medical Center, including the AMC Cancer Institute, Urologic Cancer Center, Centre for Personalised Cancer Medicine, and Theranostics Centre. His research encompasses systemic therapy, immunotherapy, targeted therapy, and clinical trial design for advanced genitourinary cancers. Prof. Lee has presented landmark research at ASCO, including Phase II data on modified FOLFIRINOX for advanced urachal cancer and renal cell carcinoma studies exploring casdatifan plus cabozantinib and KEYNOTE-564 overall survival outcomes.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Lee at Asan Medical Center, subject to hospital availability and case acceptance.
Why Consider Prof. Jae-Lyun Lee?
Prof. Jae-Lyun Lee brings focused expertise in advanced genitourinary cancers and a strong research presence in international oncology, making him a key specialist for patients with urothelial, bladder, kidney, and rare urological cancers.
Areas of Specialisation
Advanced genitourinary oncology, systemic therapy, and precision cancer care
Prof. Lee's specialisation focuses on the full spectrum of advanced urological malignancies, with particular depth in urothelial carcinoma and renal cell carcinoma.
Urothelial & Bladder Cancer
Systemic therapy for advanced and metastatic urothelial carcinoma, including bladder and upper tract disease.
- arrow_rightPlatinum-based chemotherapy for eligible patients
- arrow_rightPD-1/PD-L1 immune checkpoint inhibitor therapy
- arrow_rightFGFR-targeted therapy for FGFR-altered tumours
- arrow_rightAntibody-drug conjugate therapy including enfortumab vedotin
- arrow_rightAdvanced urachal cancer โ including clinical trial approaches
- arrow_rightUpper tract urothelial carcinoma systemic management
Renal Cell Carcinoma & Kidney Cancer
Targeted and immuno-oncology approaches for advanced and metastatic kidney cancer.
- arrow_rightVEGF-targeted therapy including sunitinib and cabozantinib
- arrow_rightCombination immunotherapy and targeted therapy approaches
- arrow_rightCasdatifan-based combination regimens under investigation
- arrow_rightAdjuvant immunotherapy including pembrolizumab (KEYNOTE-564 data)
Procedures & Treatment Approaches
Systemic oncology services for advanced genitourinary cancers
Prof. Lee's clinical work centres on systemic treatment planning for advanced and metastatic urological cancers, integrating molecular diagnostics with evidence-based therapy selection.
Systemic Therapy for GU Cancers
Medical OncologyComprehensive systemic treatment planning for advanced urothelial, bladder, and kidney cancers.
Targeted Therapy & Precision Oncology
Targeted TherapyBiomarker-guided targeted therapy selection for renal and urothelial malignancies.
Diagnostic Evaluation & Staging
DiagnosisComprehensive workup to guide treatment decisions in advanced genitourinary cancers.
Second Opinion Consultations
Second OpinionIndependent specialist review of pathology, imaging, and treatment history for urological cancers.
Research & Publications
Peer-reviewed contributions and clinical trial leadership in genitourinary oncology
Prof. Lee has made significant research contributions in urothelial carcinoma, renal cell carcinoma, and systemic therapy for advanced genitourinary cancers, presenting at ASCO and publishing in peer-reviewed journals.
Prof. Lee's active involvement in clinical trials means that eligible patients may have access to investigational treatment approaches through CancerFax-coordinated consultation at Asan Medical Center.
Education & Training
Prof. Lee completed his medical training at Yeungnam University and went on to earn his doctorate from the University of Ulsan, where he is now Professor of Oncology.
Clinical Experience
Prof. Lee has built his career entirely within the Asan Medical Center ecosystem, progressing from clinical instructor to full professor and department director, with over 15 years of experience in genitourinary oncology.
Languages & International
Prof. Lee consults in the following languages.
CancerFax coordinates professional medical interpreter support for international patients consulting through Asan Medical Center.
CancerFax can coordinate professional medical interpreter support for international patients in other languages.
How CancerFax Helps You Access Dr. Jae-Lyun Lee
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Jae-Lyun Lee's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Jae-Lyun Lee's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Jae-Lyun Lee before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Jae-Lyun Lee's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Jae-Lyun Lee's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Jae-Lyun Lee's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Jae-Lyun Lee
Prof. Lee specialises in genitourinary (urological) cancers, with particular expertise in urothelial carcinoma, bladder cancer, upper tract urothelial carcinoma, kidney cancer, renal cell carcinoma, and rare malignancies such as urachal cancer. He also treats prostate cancer as part of his GU oncology practice.
Prof. Lee is based at Asan Medical Center and Asan Cancer Hospital in Seoul, South Korea. He holds the position of Professor in the Department of Oncology at the University of Ulsan College of Medicine and is Director of the Genitourinary Cancer Center at Asan Cancer Hospital.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Lee at Asan Medical Center, subject to hospital availability and case acceptance. Please submit your reports through CancerFax for an initial review.
Submit your medical records โ including pathology reports, imaging, treatment history, and molecular profiling results โ through CancerFax using the 'Send Your Reports' button. The CancerFax team will review the documents, prepare the case, and coordinate the next steps with Asan Medical Center, subject to availability.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging, molecular profiling, and treatment history. Prof. Lee's expertise in urothelial and renal cell carcinoma makes him well suited for second-opinion consultations on these cancers. The final consultation format depends on the doctor's institution and schedule.
Prof. Lee's published work covers the full spectrum of systemic therapy for advanced urothelial cancer, including platinum-based chemotherapy, PD-1 and PD-L1 immune checkpoint inhibitor therapy, FGFR-targeted agents for FGFR-altered tumours, and antibody-drug conjugates such as enfortumab vedotin. Treatment selection is guided by the patient's pathology, molecular profile, and performance status.
Yes. Prof. Lee has presented clinical trial results at ASCO, including the ULTIMA/KCSG GU20-03 Phase II study on modified FOLFIRINOX for advanced urachal cancer (ASCO 2024) and renal cell carcinoma research at ASCO 2025. CancerFax can discuss potential trial eligibility as part of the consultation coordination process.
Connect with Jae-Lyun Lee Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.